Search research articles
Contact Us
Filters
Showing results (391-400 of 580) with videos related to
Page
of 58
Sort By:
Cancer Immunology Research
|
June 7, 2014
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade
Zachary A Cooper, Vikram R Juneja, Peter T Sage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P B Chapman, C Robert, J Larkin, et al.
Nature Medicine
|
September 18, 2012
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N Kwong, James C Costello, Huiyun Liu, et al.
Plos One
|
July 1, 2024
Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
Adam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
Biorxiv : the Preprint Server for Biology
|
September 24, 2024
A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies
Shiyou Wei, Kuang Du, Hongbin Lan, et al.
Cancer Research
|
May 6, 2017
Oncogenic RAS Regulates Long Noncoding RNA <i>Orilnc1</i> in Human Cancer
Dongmei Zhang, Gao Zhang, Xiaowen Hu, et al.
The Journal of Clinical Investigation
|
February 24, 2015
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Lawrence N Kwong, Genevieve M Boland, Dennie T Frederick, et al.
Plos One
|
October 14, 2015
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
Adam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
European Urology
|
March 12, 2021
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma
Andres F Correa, Opeyemi A Jegede, Naomi B Haas, et al.
Cancer Discovery
|
March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
Page
of 58
Search research articles
Search
Showing results (391-400 of 580) with videos related to
Sort By:
Page
of 58
Cancer Immunology Research
|
June 7, 2014
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade
Zachary A Cooper, Vikram R Juneja, Peter T Sage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P B Chapman, C Robert, J Larkin, et al.
Nature Medicine
|
September 18, 2012
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N Kwong, James C Costello, Huiyun Liu, et al.
Plos One
|
July 1, 2024
Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
Adam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
Biorxiv : the Preprint Server for Biology
|
September 24, 2024
A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies
Shiyou Wei, Kuang Du, Hongbin Lan, et al.
Cancer Research
|
May 6, 2017
Oncogenic RAS Regulates Long Noncoding RNA <i>Orilnc1</i> in Human Cancer
Dongmei Zhang, Gao Zhang, Xiaowen Hu, et al.
The Journal of Clinical Investigation
|
February 24, 2015
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Lawrence N Kwong, Genevieve M Boland, Dennie T Frederick, et al.
Plos One
|
October 14, 2015
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
Adam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
European Urology
|
March 12, 2021
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma
Andres F Correa, Opeyemi A Jegede, Naomi B Haas, et al.
Cancer Discovery
|
March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
Page
of 58